SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Emergent BioSolutions Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors


Werte in diesem Artikel
Aktien

7.08 EUR -0.10 EUR -1.46 %

NEW YORK, Aug. 8, 2023 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Emergent BioSolutions Inc. (NYSE: EBS).

If you are a shareholder of Emergent BioSolutions Inc. and are interested in obtaining additional information regarding this investigation, free of charge, please visit us at: https://pjlfirm.com/emergent-biosolutions-inc/

You may also contact Robert H. Lefkowitz, Esq. either via email at rl@pjlfirm.com or by telephone at 212-725-1000. One of our attorneys will personally speak with you about the case at no cost or obligation.

Purcell & Lefkowitz LLP is a law firm exclusively committed to representing shareholders nationwide who are victims of securities fraud, breaches of fiduciary duty and other types of corporate misconduct. For more information about the firm and its attorneys, please visit https://pjlfirm.com. Attorney advertising. Prior results do not guarantee a similar outcome. 

Cision View original content:https://www.prnewswire.com/news-releases/shareholder-alert-purcell--lefkowitz-llp-is-investigating-emergent-biosolutions-inc-for-potential-breaches-of-fiduciary-duty-by-its-board-of-directors-301895291.html

SOURCE Purcell & Lefkowitz LLP

Aktuelle Emergent BioSolutions Aktie News

Werbung

Emergent BioSolutions Analysen

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Emergent BioSolutions nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
DatumRatingAnalyst
03.08.18 Emergent BioSolutions Buy Chardan Capital Markets
16.01.18 Emergent BioSolutions Buy Chardan Capital Markets
28.06.16 Emergent BioSolutions Buy Singular Research
15.04.16 Emergent BioSolutions Buy Chardan Capital Markets
28.03.16 Emergent BioSolutions Buy Singular Research